Heart and Vessels

, Volume 11, Issue 3, pp 123–132 | Cite as

Induction of thrombolysis and prevention of thrombus formation by local drug delivery with a double-occlusion balloon catheter

  • Takanobu Tomaru
  • Yoshiharu Fujimori
  • Fumitaka Nakamura
  • Naoto Aoki
  • Yoshimitsu Sakamoto
  • Kohichi Kawai
  • Masao Omata
  • Yasumi Uchida
Originals

Summary

The efficacy of the local delivery of an antithrombotic drug in preventing thrombosis and enabling thrombolysis was investigated in 29 dogs. An antithrombotic drug (heparin, 25U/kg), or an antithrombin (argatroban, 0.05 mg/kg) was infused into injured canine iliac arteries, using a double-occlusion balloon catheter, and the preventive effect of the drug was evaluated. Local delivery of low-dose tissuetype plasminogen activator (t-PA; Tisokinase, 50 000 U; Kowa, Nagoya and Asahi Chemical Industries, Fuji, Japan) into thrombosed canine iliac arteries, using the same catheter, or intravenous infusion of low-dose or high-dose t-PA (30 000U/kg), was also performed. Angiographically, stenotic thrombosis was 2% by local delivery of argatroban and 7% by local delivery of heparin (P < 0.01 vs each control; 47% and 51% respectively). Thrombotic stenosis, as observed by angiography, decreased from 91% to 9% after local delivery of t-PA, and from 94% to 52% in controls. Local delivery of t-PA effectively reduced the thrombus size (P < 0.01 vs control). After systemic intravenous delivery of low-dose t-PA, no reduction of residual thrombotic stenosis, was observed. Reduction of residual thrombotic stenosis after intravenous delivery of high-dose t-PA, was similar to that achieved by local delivery of the drug. Angioscopy demonstrated a similar trend. High-dose drug delivery reduced systemic coagulability. Local delivery of an antithrombotic drug, using a double-occlusion balloon catheter, effectively prevented thrombus formation, and local delivery of t-PA induced thrombolysis without exerting a significant influence on coagulability.

Key words

Tissue type plasminogen activator (t-PA) Thrombolysis Double occlusion balloon catheter Local delivery 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mabin TA, Holmes DR, Smith HC, Vliestra RE, Bove AA, Reeder GS, Chesebro JH, Bresnahan JF, Orszulak TA (1985) Intracoronary thrombus. Role in colonary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 5:198–202Google Scholar
  2. 2.
    Surgrue DD, Holmes DR, Smith HC, Reeder GS, Lane GE, Vliestra RE, Bresnahan JF, Hammes LN, Piehler JM (1986) Coronary artery thrombus as a risk factor for acute vessel occlusion during percutaneous coronary angioplasty: Improved results. Br Heart J 53:62–66Google Scholar
  3. 3.
    Deligonul U, Gabliani GI, Caralis DG, Kern MJ, Vandormael MG (1988) Percutaneous coronary angioplasty in patients with intracoronary thrombus. Am J Cardiol 62:474–476Google Scholar
  4. 4.
    Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E (1983) Thrombolysis In myocardial Infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76:142–154Google Scholar
  5. 5.
    Schaer DH, Ross AM, Wasserman AG (1987) Reinfarction, recureent angina, and reocclusion after thrombolytic therapy. Circulation 76 (Suppl II):57–62Google Scholar
  6. 6.
    Bang BU, Wilhelm OG, Glayman MD (1989). After coronary thrombolysis and reperfusion, what next? J Am Coll Cardiol 14:837–849Google Scholar
  7. 7.
    Gold HK, Leinbach RC, Yasuda T, Johnson JA, Grossbard EB (1986) Acute coronary reocclusion after thrombolysis with recombinant human tissue type plasminogen activator: Prevention by a maintenance infusion. Circulation 73:347–352Google Scholar
  8. 8.
    Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, Bowie EJW, Badimon L, Fuster V (1990) Hirudin, heparin and placebo during deep arterial injury in the pig. Circulation 82:1476–1484Google Scholar
  9. 9.
    Araki H, Muramoto J, Nishi K, Jougasaki M, Inoue M (1992) Heparin adheres to the damaged arterial wall and inhibits its thrombogenicity. Circ Res 71:577–584Google Scholar
  10. 10.
    Fuster V, Badiman L, Badiman JJ, Chesebro JH (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326:242–250Google Scholar
  11. 11.
    Wollinsky H, Thung S (1990) Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol 15:475–481Google Scholar
  12. 12.
    Nunes GL, Hanson SR, King SB, Sahatjian RA, Barry JJ, Scott NA (1993) Local heparin delivery with a hydrogel-coated PTCA balloon catheter inhibits platelet-dependent thrombosis (abstract). J Am Coll Cardiol 21:117AGoogle Scholar
  13. 13.
    Nunes GL, Hanson SR, King SB, Sahatjian RA, Scott NA (1994) Local delivery of a synthetic antithrombin with a hydrogel-coated angioplasty balloon catheter inhibits platelet-dependent thrombosis. J Am Coll Cardiol 23: 1578–1583Google Scholar
  14. 14.
    Meyer BJ, Fernandez-Oritiz A, Mailhac A, Falk E, Badimon L, Michael AD, Chesebro JH, Fuster V, Badimon JJ (1994) Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation 90:2474–2480Google Scholar
  15. 15.
    Mitchel JF, Fram DB, Palme DF II, Foster R, Hirst JA, Azrin MA, Bow LM, Eldin AM, Waters DD, McKay RG (1995) Enhanced intracoronary thrombolysis with urokinase using a novel local drug delivery system. In vitro, in vivo, and clinical studies. Circulation 3:785–793Google Scholar
  16. 16.
    Tomaru T, Nakamura F, Fujimori Y, Omata M, Kawai S, Okada R, Murata Y, Uchida Y (1995) Local treatment with antithrombotic drug can prevent thrombus formation; angioscopic and angiographic study. J Am Coll Cardiol 26:1325–1332Google Scholar
  17. 17.
    Hasegawa A, Yamashita H, Kondo S, Kiyota T, Hayashi H, Yoshizaki H, Murakami A, Shiratsuchi M, Mori T (1988) Proteose peptone enhances production of tissue-type plasminogen activator from human diploid fibroblasts. Biochem Biophys, Res Commun 150:1230–1236Google Scholar
  18. 18.
    Hasegawa A, Tsuruta I, Nakajima K (1988) Characterization of tissue plasminogen activator (AK-124) and urokinase on human clot lysis. Jpn Pharm Therapeut 16(Suppl 6):163–167Google Scholar
  19. 19.
    Dingeman C, Rijken MH, Collen D (1982) Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem, 257: 6.2920–2925Google Scholar
  20. 20.
    Uchida Y, Tomaru T, Nakamura F, Sugimoto T, Furuse A, Fujimori Y, Hasegawa K (1987) Percutaneous coronary angioscopy in patients with ischemic heart disease. Am Heart J 114:1216–1221Google Scholar
  21. 21.
    Sherman CT, Litvack F, Grundfest W, Lee M, Hickey A, Chaux A, Kass R, Blanche C, Matroff J, Morgenstern L, Ganz W, Swan HJC, Forrester J (1986) Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 315:913–921Google Scholar
  22. 22.
    Tomaru T, Uchida Y, Nakamura F, Sonoki H, Tsukamoto M, Sugimoto T (1989) Enhancement of arterial thrombolysis with native tissue type plasminogen activator by pretreatment with heparin or batroxobin: an angioscopic study. Am Heart J 117:275–281Google Scholar
  23. 23.
    Mizuno K, Satomura K, Miyamoto A, Aralawa K, Shibuya T, Arai T, Kurita A, Nakamura H, Ambrose JA (1992) Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 326:287–291Google Scholar
  24. 24.
    Walford GD, Midei MM, Aversano TR, Gottlieb SO, Chew PH, Siu GO, Brin KP, Brinker JA (1991) Heparin after PTCA. Circulation 84:II-592Google Scholar
  25. 25.
    Mirshahi M, Soria J, Soria C, Faivre R, He L, Courtney M, Roitsch C, Tripier D, Caen JP (1989) Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis. Blood 74:1025–1030Google Scholar
  26. 26.
    Haskel EJ, Prager NA, Sobel BE, Abendschein DR (1991) Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 83:1048–1056Google Scholar
  27. 27.
    Lidon RM, Theroux P, Junean M, Adelman B, Maraganore J (1993) Initial experience with a direct antithrombin, hirulog in unstable angina. Anticoagulant, antithrombin and clinical effects. Circulation 86:1495–1501Google Scholar
  28. 28.
    Van den Bos AA, Deckers JW, Heyndrickx GL, Laarma GJ, Suryapranata H, Zijilstra F, Close P, Rijihierse JJMM, Buller HR, Serruys PW (1993) Safety and efficacy of recombinant hirudin (CGP 39393) versus heparin in patients with angina undergoing coronary angioplasty. Circulation 88:2058–2066Google Scholar
  29. 29.
    Tomaru T, Nakamura F, Miwa A, Fujimori Y, Omata M, Okada R, Uchida Y (1994) Antithrombin and thrombolytic effects of a new antithrombin agent. J Intervent Cardiol 7:409–419Google Scholar
  30. 30.
    Bresnahan DR, Davis JL, Holmes DR Jr, Smith HC (1985) Angiographic occurrence and clinical correlates of intraluminal coronary artery thrombus: Role of unstable angina. J Am Coll Cardiol 6:285–289Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • Takanobu Tomaru
    • 1
  • Yoshiharu Fujimori
    • 1
  • Fumitaka Nakamura
    • 1
  • Naoto Aoki
    • 2
  • Yoshimitsu Sakamoto
    • 2
  • Kohichi Kawai
    • 1
  • Masao Omata
    • 1
  • Yasumi Uchida
    • 1
  1. 1.Second Department of Internal MedicineFaculty of Medicine, University of TokyoTokyoJapan
  2. 2.Tokyo Metropolitan Research Laboratory of Public HealthDivision of PathologyTokyoJapan

Personalised recommendations